Current disease status-First occurrence of the lymphoma Posts on Medivizor
Navigation Menu

Current disease status-First occurrence of the lymphoma Posts on Medivizor

Evaluating PCR therapy for previously untreated indolent non-Hodgkin’s lymphoma

Posted by on Mar 31, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of a new chemotherapy regimen in patients with previously untreated indolent (painless) non-Hodgkin’s lymphoma (NHL). This study concluded that this regimen is effective and well-tolerated for these patients. Some background There are three common types of painless NHL....

Read More

Is nivolumab an effective treatment for relapsed and unresponsive Hodgkin lymphoma?

Posted by on Mar 16, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined if nivolumab is an effective treatment for relapsed and unresponsive Hodgkin lymphoma. This study concluded that nivolumab is an effective treatment for these patients, regardless of previous stem cell treatment status. Some background Standard treatment for patients with Hodgkin lymphoma (HL) which has relapsed or...

Read More

Evaluating the impact of interim imaging on treatment outcomes for advanced cHL

Posted by on Mar 10, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the impact of interim functional imaging (IFI) on the outcomes of treatment for advanced classical Hodgkin lymphoma (cHL). This study found that patients with positive scan results were more likely to disease progression. Some background ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) is the...

Read More

Predicting outcomes using the MIPI score for newly-diagnosed patients with MCL

Posted by on Feb 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the use of the MIPI score for patients with newly diagnosed mantle cell lymphoma (MCL). This study concluded that the MIPI score may better predict prognosis for these patients. Some background MCL is a type of non-Hodgkin’s lymphoma that significantly differs between individual patients. The MCL international...

Read More

Combining ibrutinib and umbralisib to treat relapsed/unresponsive mantle cell lymphoma

Posted by on Feb 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of ibrutinib (Imbruvica) combined with umbralisib for patients with released/unresponsive mantle cell lymphoma (MCL). This study concluded that the combination of umbralisib and ibrutinib is well tolerated and effective in these patients.  Some background Mantle cell...

Read More

Evaluating A+AVD for patients with newly diagnosed advanced Hodgkin lymphoma

Posted by on Feb 17, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of brentuximab vedotin (Adcetris) plus chemotherapy for patients with advanced (stage 3 – 4) Hodgkin’s lymphoma (HL). This study concluded that this treatment is effective for these patients. Some background The most commonly used frontline chemotherapy regimen for advanced HL...

Read More

Is BRESHAP an effective treatment for relapsed and unresponsive Hodgkin lymphoma?

Posted by on Feb 8, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined how safe and effective brentuximab vedotin (Adcedris) is when added to conventional treatments for relapsed and unresponsive Hodgkin lymphoma.  This study concluded that this treatment is safe and effective when used as part of the treatment for Hodgkin lymphoma. Some background Standard treatment for...

Read More

Long-term outcomes of radioimmunotherapy for patients with follicular lymphoma

Posted by on Jan 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of radioimmunotherapy (RIT) in patients with follicular lymphoma (FL). This study concluded that RIT is a safe and effective long-term treatment option for these patients. Some background FL is the most common type of non-Hodgkin’s lymphoma. The current standard first-line treatment for...

Read More

Evaluating BEAM conditioning for allogeneic stem cell transplantation in patients with relapsed or unresponsive lymphoma

Posted by on Jan 17, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of BEAM (carmustine, etoposide, cytarabine, and melphalan) chemotherapy before allogeneic hematopoietic cell transplantation (alloHCT; transferring healthy cells from a donor) for relapsed or unresponsive lymphoma. This study concluded that alloHCT with BEAM chemotherapy is an alternative...

Read More